Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
about
Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathwayRole of angiogenesis in endodontics: contributions of stem cells and proangiogenic and antiangiogenic factors to dental pulp regenerationProgress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancerVascular endothelial growth factor A (VEGF-A) induces endothelial and cancer cell migration through direct binding to integrin {alpha}9{beta}1: identification of a specific {alpha}9{beta}1 binding site.Corneal neovascularization: an anti-VEGF therapy review.Time-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: a prospective studyA method to assess target gene involvement in angiogenesis in vitro and in vivo using lentiviral vectors expressing shRNAVasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2.Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.Physiological Capillary Regression is not Dependent on Reducing VEGF Expression.Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma.Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancerGenetics and epigenetics of adrenocortical tumors.Inhibition of metastasis of oral squamous cell carcinoma by anti-PLGF treatment.Interplay of VEGFa and MMP2 regulates invasion of glioblastoma.COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models.PLGF inhibition impairs metastasis of larynx carcinoma through MMP3 downregulation.Molecular basis underlying inhibition of metastasis of gastric cancer by anti-VEGFa treatment.VEGF-activated miR-144 regulates autophagic survival of prostate cancer cells against Cisplatin.New antibody to stop tumor angiogenesis and lymphatic spread by blocking receptor partnering.Evaluation of Antiangiogenic Efficacy of Emilia sonchifolia (L.) DC on Tumor-Specific Neovessel Formation by Regulating MMPs, VEGF, and Proinflammatory Cytokines.Nicotinic acid inhibits angiogenesis likely through cytoskeleton remodeling.Molecular regulation of cervical cancer growth and invasion by VEGFa.Adrenocortical carcinoma
P2860
Q28385231-D838D828-B75C-4E00-A13C-DB890155C568Q28817681-0E8B3886-3F86-45CE-B9F3-289EC0870930Q33720025-C5E28BFC-0905-467A-B7AF-264792095204Q34488846-E8B8C391-4EFA-42FF-8361-E322CED2CD25Q34641522-5BF60B6C-3176-4502-BCAA-6D55AB60AFC9Q34677335-D94D630F-C565-4ACC-86DF-C01EDF9E36BEQ35156024-9A65B975-0D4E-4642-8DB7-A8A85AF59F1FQ35695381-C149A4F1-7874-46DB-8304-82518CC8EFBFQ35966757-C00ABBE3-2DF4-4333-8673-7CBF3B7D0878Q36219254-44EF0B19-5813-4B56-AAE2-682E5A157B31Q36552345-EF8428DE-AA82-4A0B-947F-EF1B0866F4F9Q36920386-BF607922-84D2-42B3-A769-29DEB929129AQ36946632-5ADB7387-3618-42AB-A018-014E3E2E543BQ37116858-0C1894F9-C2A8-48D6-9C01-F1501DE3F398Q38162079-064455C4-8C0E-4528-B7AE-B9F8E77AA0F4Q38937134-B6659E2D-4B5A-49D3-A4EA-3AF46041102DQ38957323-D8B3EFDA-8944-44AD-9C8B-23DA5D1153C4Q38981326-FA004160-037C-40EC-98D7-31410FF3DEE0Q38982896-BE6BA1B0-FB35-4F83-BEAA-B322BE62F1F8Q38992866-F4BD04E5-8F2B-4A37-8E53-9E91E05B47F5Q40323358-EE357F23-2C73-47FC-ADFD-D6479639830EQ41932420-1CCC0875-90AA-4983-8168-172FC21FF934Q47395339-E720F224-BC63-4C74-AD8C-13BAAD3470B1Q49965720-1CC51DE1-20CB-4072-8B37-CEFCC5F8BF07Q54328979-5989F3B9-4B0F-432C-BF07-3726FE85F96CQ57645859-1485632F-2F3D-4299-813D-5C9279FEA578
P2860
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
@ast
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
@en
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
@en-gb
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
@nl
type
label
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
@ast
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
@en
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
@en-gb
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
@nl
prefLabel
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
@ast
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
@en
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
@en-gb
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
@nl
P2093
P3181
P1476
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
@en
P2093
Anil Bagri
Greg D. Plowman
Hosein Kouros-Mehr
Kevin G. Leong
P304
P3181
P356
10.1016/J.MOLMED.2010.01.004
P407
P577
2010-03-01T00:00:00Z